{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:31:15Z","timestamp":1789601475430,"version":"build-2803163510"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Some people who are receiving dialysis treatment have virus infection such as hepatitis B, hepatitis C and\/or HIV that is present in their blood. These infections can be transmitted to other patients if blood is contaminated by the blood of another with a viral infection. Haemodialysis is performed by passing blood from a patient through a dialysis machine, and multiple patients receive dialysis within a dialysis unit. Therefore, there is a risk that these viruses may be transmitted around the dialysis session. This documents sets out recommendations for minimising this risk.<\/jats:p><jats:p>There are sections describing how machines and equipment should be cleaned between patients. There are also recommendations for dialysing patients with hepatitis B away from patients who do not have hepatitis B. Patients should be immunised against hepatitis B, ideally before starting dialysis if this is possible. There are guidelines on how and when to do this, for checking whether immunisation is effective, and for administering booster doses of vaccine. Finally there is a section on the measures that should be taken if a patient receiving dialysis is identified as having a new infection of hepatitis B, hepatitis C or HIV.<\/jats:p>","DOI":"10.1186\/s12882-019-1529-1","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:02:58Z","timestamp":1572220978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Clinical practice guideline management of blood borne viruses within the haemodialysis unit"],"prefix":"10.1186","volume":"20","author":[{"given":"Elizabeth","family":"Garthwaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Douthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Tyerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/bmj.3.5723.603","volume":"3","author":"AH Knight","year":"1970","unstructured":"Knight AH, Fox RA, Baillod RA, et al. Hepatitis-associated antigen and antibody in haemodialysis patients and staff. Br Med J. 1970;3:603\u20136.","journal-title":"Br Med J"},{"key":"1529_CR2","unstructured":"Report of the Rosenheim Advisory Group. Hepatitis and the treatment of chronic renal failure. Scottish Home and Health Department, Welsh Office: Department of Health and Social Security; 1972."},{"key":"1529_CR3","volume-title":"Good Practice Guidelines for Renal Dialysis\/Transplantation Units. Prevention and control of blood-borne virus infection","author":"Recommendations of a working group convened by the Public Health Laboratory Service (PHLS) on behalf of the Department of Health","year":"2002","unstructured":"Recommendations of a working group convened by the Public Health Laboratory Service (PHLS) on behalf of the Department of Health. Good Practice Guidelines for Renal Dialysis\/Transplantation Units. Prevention and control of blood-borne virus infection. 2002."},{"key":"1529_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1525-139X.2005.18108.x","volume":"18","author":"L Finelli","year":"2005","unstructured":"Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52\u201361.","journal-title":"Semin Dial"},{"key":"1529_CR5","doi-asserted-by":"crossref","unstructured":"Byrne C, Caskey F, Castledine C, Dawnay A, Ford D, Fraser S, Lambie M, Maxwell H, Steenkamp R, Wilkie M, Williams AJ. All patients receiving renal replacement therapy in the United Kingdom 2015. In: NEPHRON 2017;137 (suppl1) UK renal registry; 19th annual report of the renal association. UK Renal Registry, Bristol, UK.","DOI":"10.1159\/000481362"},{"key":"1529_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1046\/j.1525-1594.1999.06310.x","volume":"23","author":"SA Teles","year":"1999","unstructured":"Teles SA, Martins RM, Vanderborght B, Stuyver L, Gaspar AM, Yoshida CF. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs. 1999;23:1074\u20138.","journal-title":"Artif Organs"},{"key":"1529_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/jmv.21088","volume":"80","author":"E Spada","year":"2008","unstructured":"Spada E, Abbate I, Sicurezza E, et al. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit in Italy. J Med Virol. 2008;80:261\u20137.","journal-title":"J Med Virol"},{"key":"1529_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1157\/13075954","volume":"19","author":"J Castell","year":"2005","unstructured":"Castell J, Gutierrez G, Castell J, Gutierrez G. Outbreak of 18 cases of hepatitis C in a hemodialysis unit. [Spanish]. Gac Sanit. 2005;19:214\u201320.","journal-title":"Gac Sanit"},{"key":"1529_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jcv.2007.07.012","volume":"40","author":"S Ramalingam","year":"2007","unstructured":"Ramalingam S, Leung T, Cairns H, et al. Transmission of hepatitis B virus (genotype E) in a haemodialysis unit. J Clin Virol. 2007;40:105\u20139.","journal-title":"J Clin Virol"},{"key":"1529_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10096-006-0162-7","volume":"25","author":"LA Kondili","year":"2006","unstructured":"Kondili LA, Genovese D, Argentini C, et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis. 2006;25:527\u201331.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1529_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1096-9071(199910)59:2<135::AID-JMV2>3.0.CO;2-Y","volume":"59","author":"DN Irish","year":"1999","unstructured":"Irish DN, Blake C, Christophers J, et al. Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening. J Med Virol. 1999;59:135\u201340.","journal-title":"J Med Virol"},{"key":"1529_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199606063342301","volume":"334","author":"K Masuko","year":"1996","unstructured":"Masuko K, Mitsui T, Iwano K, et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med. 1996;334:1485\u201390.","journal-title":"N Engl J Med"},{"key":"1529_CR13","first-page":"1522","volume":"11","author":"JF Schlaak","year":"1996","unstructured":"Schlaak JF, Kohler H, Gerken G. Hepatitis G virus: an old, but newly discovered hepatotropic virus--is it of interest for the nephrologist? Nephrol Dial Transplant. 1996;11:1522\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1529_CR14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/jmv.21161","volume":"80","author":"S.M. Hosseini-Moghaddam","year":"2008","unstructured":"Hosseini-Moghaddam SM, Keyvani H, Samadi M, Alavian SM, Mahdavimazdeh M, Daneshvar S, Razzaghi Z. GB virus type C infection in hemodialysis patients considering co-infection with hepatitis C virus. J Med Virol. 2008;80(7):1260\u20133.","journal-title":"Journal of Medical Virology"},{"key":"1529_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(95)92603-8","volume":"345","author":"V Cardenas","year":"1995","unstructured":"Cardenas V, et al. Transmission of HIV in dialysis Centre. Lancet. 1995;345:1417\u201322.","journal-title":"Lancet"},{"issue":"1","key":"1529_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1086\/315167","volume":"181","author":"Nasr\u00a0M. El Sayed","year":"2000","unstructured":"El Sayed NM, Gomatos PJ, Beck-Sague CM, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000;181(1):91\u20137.","journal-title":"The Journal of Infectious Diseases"},{"key":"1529_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ndt\/12.2.304","volume":"12","author":"T Good","year":"1997","unstructured":"Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis Centre. Nephrol Dial Transplant. 1997;12:304\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jmv.20526","volume":"78","author":"F Hmaied","year":"2006","unstructured":"Hmaied F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185\u201391.","journal-title":"J Med Virol"},{"key":"1529_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1086\/502448","volume":"25","author":"C Sartor","year":"2004","unstructured":"Sartor C, Brunet P, Simon S, et al. Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. Infect Control Hosp Epidemiol. 2004;25:609\u201311.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1529_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1755-6686.2003.tb00277.x","volume":"29","author":"A Stragier","year":"2003","unstructured":"Stragier A, Jadoul M. Should dialysis machines be disinfected between patients' shifts? EDTNA ERCA J. 2003;29:73\u20136.","journal-title":"EDTNA ERCA J"},{"key":"1529_CR21","unstructured":"Wheeler D, Winkelmayer WC. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 2008;73:S1\u2013S99."},{"key":"1529_CR22","first-page":"183","volume":"17","author":"A Karkar","year":"2006","unstructured":"Karkar A, Abdelrahman M, Ghacha R, et al. Prevention of viral transmission in HD units: the value of isolation. Nasrat Amrad Wa Ziraat Alkulat. 2006;17:183\u20138.","journal-title":"Nasrat Amrad Wa Ziraat Alkulat"},{"key":"1529_CR23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/0002-9343(91)90638-E","volume":"90","author":"R Marcus","year":"1991","unstructured":"Marcus R, Favero MS, Banerjee S, et al. Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. The cooperative Dialysis study group. Am J Med. 1991;90:614\u20139.","journal-title":"Am J Med"},{"key":"1529_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/j.1523-1755.1998.00823.x","volume":"53","author":"M Jadoul","year":"1998","unstructured":"Jadoul M, Cornu C, van Ypersele dS, Jadoul M, Cornu C, Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaires Cliniques St-Luc (UCL) collaborative group. Kidney Int. 1998;53:1022\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"1529_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5301\/ijao.5000376","volume":"38","author":"Fabrizio Fabrizi","year":"2015","unstructured":"Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38(1):1\u20137. https:\/\/doi.org\/10.5301\/ijao.5000376 Epub 2015 Jan 26.","journal-title":"The International Journal of Artificial Organs"},{"key":"1529_CR26","unstructured":"www.cdc.gov\/hepatitis\/outbreaks ; Healtth-care associated Hepatitis B and C outbreaks reported to CDC and Prevention. 2008\u20132016."},{"key":"1529_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-7-15","volume":"7","author":"S Lanini","year":"2009","unstructured":"Lanini S, Puro V, Lauria FR, Fusco FM, NIsii C, Ippolito G. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med. 2009;7:15. https:\/\/doi.org\/10.1186\/1741-7015-7-15 .","journal-title":"BMC Med"},{"key":"1529_CR28","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S0140-6736(73)92860-2","volume":"2","author":"MS Favero","year":"1973","unstructured":"Favero MS, Maynard JE, Petersen NJ, et al. Letter: Hepatitis-B antigen on environmental surfaces. Lancet. 1973;2:1455.","journal-title":"Lancet"},{"key":"1529_CR29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0272-6386(03)00787-X","volume":"42","author":"N Froio","year":"2003","unstructured":"Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546\u201350.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000013565","volume":"20","author":"O AlFurayh","year":"2000","unstructured":"AlFurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 2000;20:103\u20136.","journal-title":"Am J Nephrol"},{"key":"1529_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000188000","volume":"67","author":"AC Kroes","year":"1994","unstructured":"Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron. 1994;67:369.","journal-title":"Nephron"},{"key":"1529_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000045166","volume":"80","author":"R Valtuille","year":"1998","unstructured":"Valtuille R, Fernandez JL, Berridi J, et al. Evidence of hepatitis C virus passage across dialysis membrane. Nephron. 1998;80:194\u20136.","journal-title":"Nephron"},{"key":"1529_CR33","first-page":"434","volume":"4","author":"E Lindley","year":"2011","unstructured":"Lindley E, Boyle G, Gandy D, et al. How plausible is hepatitis C virus via the haemodialysis circuit. NDT Plus. 2011;4:434\u20136.","journal-title":"NDT Plus"},{"key":"1529_CR34","doi-asserted-by":"crossref","unstructured":"Wheeler D, Winkelmayer WC. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 2018;8:S91\u2013S165.","DOI":"10.1016\/j.kisu.2018.06.001"},{"key":"1529_CR35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0272-6386(05)80017-4","volume":"37","author":"N Petrosillo","year":"2001","unstructured":"Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis.[see comment]. Am J Kidney Dis. 2001;37:1004\u201310.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000076951","volume":"13","author":"AK Saxena","year":"2004","unstructured":"Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract. 2004;13:129\u201335.","journal-title":"Med Princ Pract"},{"key":"1529_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2307\/30141401","volume":"19","author":"AC Kroes","year":"1998","unstructured":"Kroes AC, van Bommel EF, Kluytmans JA, et al. Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses. Infect Control Hosp Epidemiol. 1998;19:508\u201310.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1529_CR38","unstructured":"http:\/\/webarchive.nationalarchives.gov.uk\/+\/http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_078134"},{"key":"1529_CR39","first-page":"RR-5","volume":"50","author":"CDC","year":"2001","unstructured":"CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. 2001;50:RR-5.","journal-title":"MMWR"},{"key":"1529_CR40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7326\/0003-4819-99-3-330","volume":"99","author":"MJ Alter","year":"1983","unstructured":"Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med. 1983;99:330\u20133.","journal-title":"Ann Intern Med"},{"key":"1529_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1046\/j.1365-2893.2002.00374.x","volume":"9","author":"S Kokubo","year":"2002","unstructured":"Kokubo S, Horii T, Yonekawa O, Ozawa N, Mukaide M. A phylogenetictree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat. 2002;9:450\u20134.","journal-title":"J Viral Hepat"},{"key":"1529_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5301\/ijao.5000437","volume":"38","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38:471\u201380.","journal-title":"Int J Artif Organs"},{"key":"1529_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-7-15","volume":"7","author":"S Lanini","year":"2009","unstructured":"Lanini S, Puro V, Lauria F, Fusco F, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med. 2009;7:15.","journal-title":"BMC Med"},{"key":"1529_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.0894-0959.2004.17339.x","volume":"17","author":"JI Tokars","year":"2004","unstructured":"Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004;17:310\u20139.","journal-title":"Semin Dial"},{"key":"1529_CR45","unstructured":"https:\/\/www.cdc.gov.mmwr\/preview\/mmwrhtml\/mm5732a3.htm . Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials."},{"key":"1529_CR46","first-page":"445","volume":"165","author":"BW Moloughney","year":"2001","unstructured":"Moloughney BW. Transmission and postexposure management of blood borne virus infections in the health care setting: where are we now? CMAJ. 2001;165:445\u201351.","journal-title":"CMAJ"},{"key":"1529_CR47","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0272-6386(03)00787-X","volume":"42","author":"N Froio","year":"2003","unstructured":"Froio N, Nicastri E, Comandini U, et al. Contamination of hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546\u201350.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR48","first-page":"897","volume-title":"Hospital Epidemiology and Infection Controled 2","author":"M Favero","year":"1999","unstructured":"Favero M, Tokars J, Arduino M, et al. Nosocomial infections associated with hemodialysis. In: Mayall CG, editor. Hospital Epidemiology and Infection Controled 2. Philadelphia: Lippincott Williams and Wilkens; 1999. p. 897\u2013917."},{"key":"1529_CR49","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/infdis\/153.6.1149","volume":"153","author":"M Alter","year":"1986","unstructured":"Alter M, Favero M, Maynard J. Impact of infection control strategies on the incidence of dialysis- associated hepatitis in the United States. J Infect Dis. 1986;153:1149\u201351.","journal-title":"J Infect Dis"},{"key":"1529_CR50","volume-title":"National surveillance of dialysis associated diseases in the United States","author":"JI Tokars","year":"1994","unstructured":"Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States; 1994."},{"issue":"Suppl 7","key":"1529_CR51","first-page":"78","volume":"17","author":"European Best Practice Guidelines for Haemodialysis (part 1)","year":"2002","unstructured":"European Best Practice Guidelines for Haemodialysis (part 1). Guideline V1.6: prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant. 2002;17(Suppl 7):78\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR52","doi-asserted-by":"crossref","unstructured":"Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev. 2016;8:CD006420.","DOI":"10.1002\/14651858.CD006420.pub2"},{"key":"1529_CR53","first-page":"32","volume":"4","author":"P Thomson","year":"2011","unstructured":"Thomson P, Williams C, Aitken C, et al. A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine. NDT Plus. 2011;4:32\u20135.","journal-title":"NDT Plus"},{"key":"1529_CR54","unstructured":"https:\/\/renal.org\/wp-content\/uploads\/2017\/06\/blood-borne-viruses-5th-edition-1.pdf"},{"key":"1529_CR55","first-page":"1","volume":"50","author":"U.S. Department of Health and Human Services. Centers for Disease Control and Prevention (CDC)","year":"2001","unstructured":"U.S. Department of Health and Human Services. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1.","journal-title":"MMWR Recomm Rep"},{"key":"1529_CR56","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/0002-9343(91)90638-E","volume":"90","author":"R Marcus","year":"1991","unstructured":"Marcus R, Favero MS, Banerjee S, et al. Prevalence and incidence of human immunodeficiency virus among patients undergoing longterm hemodialysis. The cooperative Dialysis study group. Am J Med. 1991;90:614\u20139.","journal-title":"Am J Med"},{"key":"1529_CR57","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/ajkd.2003.50036","volume":"41","author":"TS Ahuja","year":"2003","unstructured":"Ahuja TS, O'brien WA. Special issues in the management of patients with ESRD and HIV infection. Am J Kidney Dis. 2003;41:279.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR58","unstructured":"U.S.Food and Drug Administration. Center for Devices and Radiological Health. FDA safety alert: Potential cross-contamination linked to hemodialysis treatment. www.fdagov\/cdrh\/safety\/althin.html [serial online] 99 A.D.; Accessed 25 Aug 8 A.D."},{"key":"1529_CR59","unstructured":"Health Canada: Therapeutic Products Directorate. Notice to hospitals: Hemodialysis units and blood tubing sets incorporating a transducer protector. Health Canada [serial online] 2004;Accessed 2 Sept 2008."},{"key":"1529_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.nephro.2005.03.006","volume":"1","author":"P Brunet","year":"2005","unstructured":"Brunet P, Frenkian G, Girard AM, et al. Backward flow of blood in the extracorporal circuit pressure transducers of the generator-monitors of hemodialysis. [French]. Nephrol Ther. 2005;1:157\u201360.","journal-title":"Nephrol Ther"},{"key":"1529_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1017\/S0195941700082734","volume":"23","author":"E Delarocque-Astagneau","year":"2002","unstructured":"Delarocque-Astagneau E, Baffoy N, Thiers V, et al. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol. 2002;23:328\u201334.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1529_CR62","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1086\/502613","volume":"26","author":"A Savey","year":"2005","unstructured":"Savey A, Simon F, Izopet J, et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center.[erratum appears in infect control Hosp Epidemiol. 2005 Oct; 26(10):810]. Infect Control Hosp Epidemiol. 2005;26:752\u201360.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1529_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000188000","volume":"67","author":"AC Kroes","year":"1994","unstructured":"Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron. 1994;67:369.","journal-title":"Nephron"},{"key":"1529_CR64","unstructured":"https:\/\/www.drugabuse.gov\/publications\/research-reports\/hivaids\/who-risk-hiv-infection-which-populations-are-most-affected"},{"key":"1529_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0195-6701(95)90249-X","volume":"30","author":"M Roll","year":"1995","unstructured":"Roll M, Norder H, Magnius LO, Grillner L, Lindgren V. Nosocomial spread of hepatitis B virus (HBV) in a haemodialysis unit confirmed by HBV DNA sequencing. J Hosp Infect. 1995;30:57\u201363.","journal-title":"J Hosp Infect"},{"issue":"52","key":"1529_CR66","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.1016\/j.vaccine.2011.10.057","volume":"29","author":"SS Chaves","year":"2011","unstructured":"Chaves SS, Daniels D, Cooper BW, et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine. 2011;29(52):9618\u201323.","journal-title":"Vaccine."},{"key":"1529_CR67","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.20435","volume":"40","author":"GY Minuk","year":"2004","unstructured":"Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B virus infection in a north American adult hemodialysis patient population. Hepatology. 2004;40:1072\u20137.","journal-title":"Hepatology"},{"key":"1529_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/1744-9987.12241","volume":"1","author":"T Saijo","year":"2015","unstructured":"Saijo T, Joki N, Inishi Y, Muto M, Saijo M, Hase H. Occult hepatitis B virus infection in hemodialysis patients in Japan. Ther Apher Dial. 2015;1:125\u201330.","journal-title":"Ther Apher Dial"},{"issue":"Suppl 1","key":"1529_CR69","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1386-6532(06)80007-7","volume":"36","author":"CJ Liu","year":"2006","unstructured":"Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006;36(Suppl 1):S33\u201344.","journal-title":"J Clin Virol"},{"key":"1529_CR70","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1053\/jhep.2003.50456","volume":"38","author":"CJ Liu","year":"2003","unstructured":"Liu CJ, Kao JH, Chen DS. Molecular assays for hepatitis B virus infection. Hepatology. 2003;38:1311.","journal-title":"Hepatology"},{"key":"1529_CR71","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1159\/000117573","volume":"28","author":"M Rahnavardi","year":"2008","unstructured":"Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28:628\u201340.","journal-title":"Am J Nephrol"},{"key":"1529_CR72","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","volume":"65","author":"H Midgard","year":"2016","unstructured":"Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33\u201345.","journal-title":"J Hepatol"},{"key":"1529_CR73","unstructured":"https:\/\/www.gov.uk\/government\/collections\/migrant-health-guide-countries-a-to-z"},{"key":"1529_CR74","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1046\/j.1537-2995.2000.40101198.x","volume":"40","author":"AM Courouce","year":"2000","unstructured":"Courouce AM, Le Marrec N, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion. 2000;40:1198\u2013202.","journal-title":"Transfusion"},{"key":"1529_CR75","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2036.2005.02416.x","volume":"21","author":"F Fabrizi","year":"2005","unstructured":"Fabrizi F, de Vecchi AF, Como G, et al. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther. 2005;21:861\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1529_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/sdi.12097","volume":"26","author":"C Mbaeyi","year":"2013","unstructured":"Mbaeyi C, Thompson ND. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities. Semin Dial. 2013;26:439\u201346.","journal-title":"Semin Dial"},{"key":"1529_CR77","first-page":"108","volume":"43","author":"JI Tokars","year":"1997","unstructured":"Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States--1994. ASAIO J. 1997;43:108\u201319.","journal-title":"ASAIO J"},{"key":"1529_CR78","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/00002480-199339040-00027","volume":"39","author":"JI Tokars","year":"1993","unstructured":"Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of dialysis associated diseases in the United States, 1991. ASAIO J. 1993;39:966\u201375.","journal-title":"ASAIO J"},{"key":"1529_CR79","doi-asserted-by":"crossref","unstructured":"Hepatitis B in retreat from dialysis units in United Kingdom in 1973. Public health laboratory service survey. Br Med J. 1976;1:1579\u201381.","DOI":"10.1136\/bmj.1.6025.1579"},{"key":"1529_CR80","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.1981.03310270033020","volume":"245","author":"GR Najem","year":"1981","unstructured":"Najem GR, Louria DB, Thind IS, et al. Control of hepatitis B infection. The role of surveillance and an isolation hemodialysis center. JAMA. 1981;245:153\u20137.","journal-title":"JAMA"},{"key":"1529_CR81","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","volume":"65","author":"RB Fissell","year":"2004","unstructured":"Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335\u201342.","journal-title":"Kidney Int"},{"key":"1529_CR82","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/ndt\/gfh012","volume":"19","author":"M Jadoul","year":"2004","unstructured":"Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR83","first-page":"621","volume":"90","author":"MW Taal","year":"2000","unstructured":"Taal MW, Zyl-Smit R. Hepatitis C virus infection in chronic haemodialysis patients--relationship to blood transfusions and dialyser re-use. S Afr Med J. 2000;90:621\u20135.","journal-title":"S Afr Med J"},{"issue":"12","key":"1529_CR84","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1177\/039139880803101204","volume":"31","author":"F Fabrizi","year":"2008","unstructured":"Fabrizi F, Messa P, Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int J Artif Organs. 2008;31(12):1004\u201316.","journal-title":"Int J Artif Organs"},{"issue":"Suppl 7","key":"1529_CR85","first-page":"78","volume":"17","author":"European Best Practice Guidelines for Haemodialysis (Part 1)","year":"2002","unstructured":"European Best Practice Guidelines for Haemodialysis (Part 1). Guideline VI.6: prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant. 2002;17(Suppl 7):78\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR86","first-page":"859","volume":"31","author":"O Harmankaya","year":"2002","unstructured":"Harmankaya O, Cetin B, Erimez D, et al. Patient isolation prevents the transmission of hepatitis C virus infection in hemodialysis units. Dial Transplant. 2002;31:859\u201361.","journal-title":"Dial Transplant"},{"issue":"Suppl 2","key":"1529_CR87","first-page":"ii294","volume":"27","author":"P Dzekova-Vidimliski","year":"2012","unstructured":"Dzekova-Vidimliski P, Pavleska-Kuzmanovska S, Trajceska L, et al. Decreasing prevalence of hepatitis C virus infection in hemodialysis patients: Following KDIGO guidelines. Nephrol Dial Transplant. 2012;27(Suppl 2):ii294.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR88","doi-asserted-by":"publisher","first-page":"c1","DOI":"10.1159\/000093252","volume":"104","author":"E Gallego","year":"2006","unstructured":"Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1\u20136.","journal-title":"Nephron Clin Pract"},{"key":"1529_CR89","first-page":"119","volume":"81","author":"AM Shebeb","year":"2006","unstructured":"Shebeb AM, Kotkat AM, Abd El Reheim SM, et al. An intervention study for prevention of HCV infection in some hemodialysis units in Alexandria. J Egypt Public Health Assoc. 2006;81:119\u201341.","journal-title":"J Egypt Public Health Assoc"},{"key":"1529_CR90","doi-asserted-by":"publisher","first-page":"c133","DOI":"10.1159\/000191208","volume":"111","author":"SK Agarwal","year":"2009","unstructured":"Agarwal SK, Dash SC, Gupta S, et al. Hepatitis C virus infection in haemodialysis: the \u2018no-isolation\u2019 policy should not be generalized. Nephron Clin Pract. 2009;111:c133\u201340 (ref 18).","journal-title":"Nephron Clin Pract"},{"key":"1529_CR91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jmv.1890430417","volume":"43","author":"T Allander","year":"1994","unstructured":"Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43:415\u20139.","journal-title":"J Med Virol"},{"key":"1529_CR92","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/ki.1994.301","volume":"46","author":"N Simon","year":"1994","unstructured":"Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int. 1994;46:504\u201311.","journal-title":"Kidney Int"},{"key":"1529_CR93","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ndt\/12.2.304","volume":"12","author":"KJ McLaughlin","year":"1997","unstructured":"McLaughlin KJ, Cameron SO, Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis Centre. Nephrol Dial Transplant. 1997;12:304\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR94","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(95)92603-8","volume":"345","author":"M Velandia","year":"1995","unstructured":"Velandia M, Fridkin SK, Cardenas V, et al. Transmission of HIV in dialysis Centre. Lancet. 1995;345:1417\u201322.","journal-title":"Lancet"},{"key":"1529_CR95","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1086\/315167","volume":"181","author":"NM El Sayed","year":"2000","unstructured":"El Sayed NM, Gomatos PJ, Beck-Sague CM, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000;181:91\u20137.","journal-title":"J Infect Dis"},{"key":"1529_CR96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2369-5-13","volume":"5","author":"AA Shamshirsaz","year":"2004","unstructured":"Shamshirsaz AA, Kamgar M, Bekheirnia MR, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol. 2004;5:13.","journal-title":"BMC Nephrol"},{"key":"1529_CR97","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1067\/mic.2003.55","volume":"31","author":"AK Saxena","year":"2003","unstructured":"Saxena AK, Panhotra BR, Sundaram DS, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control. 2003;31:26\u201333.","journal-title":"Am J Infect Control"},{"key":"1529_CR98","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJM198408233110803","volume":"311","author":"CE Stevens","year":"1984","unstructured":"Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984;311:496\u2013501.","journal-title":"N Engl J Med"},{"key":"1529_CR99","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0272-6386(99)70312-4","volume":"33","author":"ER Miller","year":"1999","unstructured":"Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33:356\u201360.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR100","first-page":"240","volume":"10","author":"NM Cendoroglo","year":"1995","unstructured":"Cendoroglo NM, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant. 1995;10:240\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1529_CR101","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0264-410X(93)90278-6","volume":"11","author":"AF Lefebure","year":"1993","unstructured":"Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine. 1993;11(4):397\u20139.","journal-title":"Vaccine"},{"issue":"923","key":"1529_CR102","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/pmj.78.923.538","volume":"78","author":"K Bel'eed","year":"2002","unstructured":"Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002;78(923):538\u201340.","journal-title":"Postgrad Med J"},{"key":"1529_CR103","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/infdis\/137.2.131","volume":"137","author":"AM Prince","year":"1978","unstructured":"Prince AM, Szmuness W, Mann MK, et al. Hepatitis B immune globulin: final report of a controlled, multicenter trial of efficacy in prevention of dialysis-associated hepatitis. J Infect Dis. 1978;137:131\u201344.","journal-title":"J Infect Dis"},{"key":"1529_CR104","unstructured":"https:\/\/www.gov.uk\/government\/collections\/immunisation-against-infectious-disease-the-green-book"},{"key":"1529_CR105","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(81)92679-9","volume":"1","author":"J Crosnier","year":"1981","unstructured":"Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet. 1981;1:797\u2013800.","journal-title":"Lancet"},{"key":"1529_CR106","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0140-6736(81)91847-X","volume":"1","author":"J Crosnier","year":"1981","unstructured":"Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, medical staff. Lancet. 1981;1:455\u20139.","journal-title":"Lancet"},{"key":"1529_CR107","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/ki.1984.18","volume":"25","author":"H Kohler","year":"1984","unstructured":"Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int. 1984;25:124\u20138.","journal-title":"Kidney Int"},{"key":"1529_CR108","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1053\/j.ajkd.2003.08.019","volume":"42","author":"G DaRoza","year":"2003","unstructured":"DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42:1184\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR109","unstructured":"Ridley L, Jones C. An audit of a programme of proactive pre-dialysis vaccination against hepatitis B., . [Abstract]Ridley L, Jones C. British Renal Congress 2008; Glasgow, May 2008."},{"key":"1529_CR110","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/infdis\/157.2.332","volume":"157","author":"B Seaworth","year":"1988","unstructured":"Seaworth B, Drucker J, Starling J, et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157:332\u20137.","journal-title":"J Infect Dis"},{"key":"1529_CR111","unstructured":"Grzegorzewska, Alicja E. \u201cHepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients.\u201d Hepatitis Monthly 12.11 (2012): e7359. PMC. Web. 6 Dec. 2017."},{"issue":"2","key":"1529_CR112","first-page":"183","volume":"47","author":"SK Agarwal","year":"1999","unstructured":"Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India. 1999;47(2):183\u20135.","journal-title":"J Assoc Physicians India"},{"key":"1529_CR113","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1056\/NEJM199701163360307","volume":"336","author":"SM Lemon","year":"1997","unstructured":"Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:196\u2013204.","journal-title":"N Engl J Med"},{"key":"1529_CR114","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/08860220601166263","volume":"29","author":"H Micozkadioglu","year":"2007","unstructured":"Micozkadioglu H, Zumrutdal A, Torun D, et al. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail. 2007;29:285\u20138.","journal-title":"Ren Fail"},{"key":"1529_CR115","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0272-6386(98)70081-2","volume":"32","author":"T Propst","year":"1998","unstructured":"Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis. 1998;32:1041\u20135.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR116","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1053\/j.ajkd.2003.12.052","volume":"43","author":"KF Chau","year":"2004","unstructured":"Chau KF, Cheng YL, Tsang DN, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis. 2004;43:910\u20137.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR117","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/01.MAT.0000161935.66158.97","volume":"51","author":"J Roozbeh","year":"2005","unstructured":"Roozbeh J, Moini M, Lankarani KB, Sagheb MM, Shahpoori S, Bastani B. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J. 2005;51:242\u20135.","journal-title":"ASAIO J"},{"issue":"Suppl","key":"1529_CR118","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/0264-410X(90)90218-B","volume":"8","author":"M Bruguera","year":"1990","unstructured":"Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del RG, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine. 1990;8(Suppl):S47\u20139.","journal-title":"Vaccine"},{"key":"1529_CR119","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/ndt\/12.6.1204","volume":"12","author":"F Fabrizi","year":"1997","unstructured":"Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospectiverando mized study with cost-effectiveness evaluation. Nephrol Dial Transplant. 1997;12:1204\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"1529_CR120","first-page":"44","volume":"9","author":"Y Oguz","year":"2001","unstructured":"Oguz Y, Doganci L, Vural A. Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients. Cent Eur J Public Health. 2001;9:44\u20135.","journal-title":"Cent Eur J Public Health"},{"key":"1529_CR121","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0272-6386(12)80375-1","volume":"23","author":"AL Marangi","year":"1994","unstructured":"Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994;23:537\u201342.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR122","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/ajkd.2000.19099","volume":"36","author":"AF Charest","year":"2000","unstructured":"Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis. 2000;36:976\u201382.","journal-title":"Am J Kidney Dis"},{"key":"1529_CR123","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","volume":"68","author":"NK Tong","year":"2005","unstructured":"Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68:2298\u2013303.","journal-title":"Kidney Int"},{"key":"1529_CR124","first-page":"138","volume":"54","author":"TG Evans","year":"2000","unstructured":"Evans TG, Schiff M, Graves B, et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic haemodialysis patients who have failed primary vaccination. Clin Nephrol. 2000;54:138\u201342.","journal-title":"Clin Nephrol"},{"issue":"Suppl 1","key":"1529_CR125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02919065","volume":"4","author":"PJ Grob","year":"1985","unstructured":"Grob PJ, Binswanger U, Blumberg A, et al. Thymopentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies. Surv Immunol Res. 1985;4(Suppl 1):107\u201315.","journal-title":"Surv Immunol Res"},{"issue":"3","key":"1529_CR126","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jama.1988.03720030025027","volume":"259","author":"JA Arevalo","year":"1988","unstructured":"Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and for hepatitis B virus. JAMA. 1988;259(3):365\u20139.","journal-title":"JAMA"},{"issue":"6","key":"1529_CR127","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/jech.46.6.587","volume":"46","author":"GM Ginsberg","year":"1992","unstructured":"Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health. 1992;46(6):587\u201394.","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"1529_CR128","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jmv.21035","volume":"80","author":"D Avazova","year":"2008","unstructured":"Avazova D, Kurbanov F, Tanaka Y, Sugiyama M, Radchenko I, Ruziev D, et al. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J Med Virol. 2008;80(2):217\u201324.","journal-title":"J Med Virol"},{"key":"1529_CR129","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJM198607243150401","volume":"315","author":"SC Hadler","year":"1986","unstructured":"Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209\u201314.","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"1529_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2893.1997.tb00155.x","volume":"4","author":"WF Carman","year":"1997","unstructured":"Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997;4(suppl 1):11.","journal-title":"J Viral Hepat"},{"key":"1529_CR131","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/01.tp.0000202731.01530.cb","volume":"81","author":"V Moal","year":"2006","unstructured":"Moal V, Vacher-Coponat H, Botelho E, et al. Emergence of hepatitis B infection despite antibodies to hepatitis B surface antigen: a new nosocomial risk in patients with end-stage renal disease. Transplantation. 2006;81:1358\u20139.","journal-title":"Transplantation"},{"key":"1529_CR132","first-page":"251","volume":"22","author":"SJ Fleming","year":"1991","unstructured":"Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Inf Secur. 1991;22:251\u20137.","journal-title":"J Inf Secur"},{"key":"1529_CR133","first-page":"47","volume":"48","author":"VM Delle","year":"1996","unstructured":"Delle VM, Caraccio V, Iberti M, et al. Hepatitis B vaccine in dialyzed patients: persistence of antibody titres after a 48-month follow-up. [Italian]. Minerva Urol Nefrol. 1996;48:47\u201350.","journal-title":"Minerva Urol Nefrol"},{"key":"1529_CR134","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0196-6553(95)90057-8","volume":"23","author":"N Petrosillo","year":"1995","unstructured":"Petrosillo N, Puro V, Jagger J, et al. The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian multicenter study on nosocomial and occupational risk of infections in Dialysis. Am J Infect Control. 1995;23:278\u201385.","journal-title":"Am J Infect Control"},{"key":"1529_CR135","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1159\/000187095","volume":"62","author":"G Berlyne","year":"1992","unstructured":"Berlyne G, Kaczmarek RG, Hamburger S, et al. Seroprevalence of antibodies to the human immunodeficiency virus in dialysis workers: results of a multi-center study. Nephron. 1992;62:441\u20133.","journal-title":"Nephron"},{"issue":"3","key":"1529_CR136","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1515\/jtim-2015-0018","volume":"3","author":"B Bernieh","year":"2015","unstructured":"Bernieh B. Viral Hepatitis in Haemodialysis - an update. J Transl Int Med. 2015;3(3):93\u2013105.","journal-title":"J Transl Int Med"},{"key":"1529_CR137","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJM198212093072403","volume":"307","author":"W Szmuness","year":"1982","unstructured":"Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982;307:1481\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"1529_CR138","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"Jean-Michel Pawlotsky","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026 .","journal-title":"Journal of Hepatology"},{"key":"1529_CR139","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/hep.20119","volume":"39","author":"DB Strader","year":"2004","unstructured":"Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147\u201371.","journal-title":"Hepatology"},{"key":"1529_CR140","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.20435","volume":"40","author":"GY Minuk","year":"2004","unstructured":"Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B virus infection in a north American adult hemodialysis patient population. Hepatology. 2004;40:1072\u20137.","journal-title":"Hepatology"},{"key":"1529_CR141","unstructured":"www.cdc.gov\/hepatitis\/outbreaks ; Health-care associated Hepatitis B and C outbreaks reported to CDC and Prevention. 2008\u20132016."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1529-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T19:43:27Z","timestamp":1664739807000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1529-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1529-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Granted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors made declarations of interest in line with the policy in the Renal Association Clinical Practice Guidelines Development Manual. Further details can be obtained on request from the Renal Association.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}